Dr. Diamond’s Metacine is eyeing product expansion.
The brand is debuting its first eye product, the Contour Collection Eyelift Bioremodeling Peptide Multiplex, which launches on the brand’s website April 16 for $225.
For the brand, which has seen growth despite headwinds in luxury skin care, the product was born out of demand that cofounder and plastic surgeon Jason Diamond saw in his practice.
“The lower eyelid area is some of the thinnest skin on the body and it’s often the first place that people notice their aging,” he said. “When people come in to see me, in regards to their aging and wanting to look more youthful, it’s often the eyelids they notice first, and as early as early 30s, people notice hollowness.”
Related Articles
Diamond treats concerns around the eye with a combination of surgical and non-surgical methods, which he’s dubbed as “Diamond Facial Eye Contouring,” hence the name of both the product and the collection it inaugurates.
“Part of the idea behind the line was finding a way to bring proprietary treatments to skin care products,” said Dr. Jessica Combs, cofounder and chief executive officer. “This is another one of those. It’s part of the contour collection, and it’s based on these procedures. You’ll see another product come out in the fall.”
Dr. Diamond’s Metacine came to market with the InstaFacial collection, which is meant to mimic in-office microneedling with platelet-rich plasma as well as lasers and injectibles, where relevant. “The initial products are allover face products. These are more targeted,” Combs said.
Combs said the business has tripled in size since its launch; in 2025 retail sales were estimated to reach $15 million and $20 million.
Eyelift contains a peptide complex, topical hyaluronic acid filler, a hyaluronic acid-retinoid complex, daisy, hawkweed, arnica, chestnut seed extract and hydrolyzed rhodophycea extract. “It’s this idea of making a targeted, clinically validated serum that accelerates your own skin’s natural bioremodeling processes around the eye and addresses major signs of aging,” Combs said. “Puffiness, hollowness, fine lines, crow’s feet, crepiness of the upper lid, dark circles, hyperpigmentation. We tried to find something that would address all of these issues.”
While clinical testing is still underway, early results are promising. Combs said that four-week data shows 96 percent of testers showed improvement in upper eyelid crepiness and eye contours and 100 percent of people had improvement in undereye dark circles and firmness.
In terms of the formula, “Each of the 12 bioactive ingredients are addressing a different concern,” said Tammy Goodarzi, cofounder and chief brand officer. “Each of them are addressing a different concern we’re addressing either with Botox or filler, or Dr. Diamond excising skin of the upper lid.”